Skip to main content

Heron Therapeutics Value Stock - Dividend - Research Selection

Heron therapeutics

ISIN: US4277461020 , WKN: A1XB6K

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield%
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Heron Therapeutics, Inc., a biotechnology company, engages in developing medicines to address unmet medical needs. The company\'s product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron) extended-release injection for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens. The company is also developing CINVANTI, a neurokinin-1 receptor antagonist aprepitant for the prevention of CINV; and HTX-011, which is in Phase III clinical development for the prevention of post-operative pain. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.
The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Heron Therapeutics, Inc. (NASDAQ:HRTX) Q4 2022 Earnings Call Transcript

2023-03-27
Heron Therapeutics, Inc. (NASDAQ:HRTX) Q4 2022 Earnings Call Transcript March 23, 2023 Operator: Good day, ladies and gentlemen. Thank you for standing by. Welcome to the Heron Therapeutics Fourth Quarter 2022 Earnings Conference. As a reminder, this conference is being recorded. And now I would like to turn the call over to David Szekeres, Executive […]

Health Care Up on Defensive Demand -- Health Care Roundup

2023-03-24
Health-care companies rallied as traders rotated into sectors less exposed to the fallout of bank failures. Shares of Heron Therapeutics rose after the...

Q4 2022 Heron Therapeutics Inc Earnings Call

2023-03-24
Q4 2022 Heron Therapeutics Inc Earnings Call

Heron stock falls ~10% as headwinds for Zynrelef label, device delivery linger

2023-03-24
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Dermata, GH Research top healthcare gainers; BridgeBio, Cidara among losers

2023-03-24
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Fly Intel: Pre-market Movers

2023-03-24
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

4 stocks to watch on Friday: Deutsche Bank, JOANN and more

2023-03-24
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Analysts Offer Insights on Healthcare Companies: Heron Therapeutics (HRTX), Monopar Therapeutics Inc (MNPR) and Werewolf Therapeutics (HOWL)

2023-03-24
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Heron Therapeutics Shares Rise Premarket as 4Q Results Top Views >HRTX

2023-03-24
By Colin Kellaher Shares of Heron Therapeutics Inc. rose more than 10% in premarket trading Friday after the biotechnology company posted...

Heron Therapeutics price target lowered to $10 from $15 at Evercore ISI

2023-03-24
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.